Quibim, a leading healthtech company pioneering the use of imaging biomarkers for precision medicine, has successfully raised a sum of $50 million in Series A financing.
Led by Asabys (through its fund Sabadell Asabys II) and Buenavista Equity Partners (through the BHG I fund, created in partnership with Columbus Venture Partners), the round saw further participation coming from new investors like UI Investissements and GoHub Ventures.
It was also joined by various existing investors, including Amadeus Capital Partners, APEX Ventures, Partech, Adara Ventures and Leadwind (KFund’s early growth fund), as well as individual investors, including Tony Fadell, Build Collective Principal, Nest founder and inventor of the iPod, and Dr. Jonathan Milner, founder of Abcam plc.
“Asabys is thrilled to support Quibim in transforming the imaging diagnostics space,” said Guillem Masferrer, Partner at Asabys Partners. “Their ability to combine AI with imaging biomarker discovery addresses critical unmet needs in oncology, neurology, and beyond. We are confident that Quibim’s innovative solutions will have a profound impact on global healthcare.”
According to certain reports, Quibim will use these newly-raised funds to facilitate the expansion of its solutions throughout US, solutions that are already cleared by the FDA. Once established across the board, this technology will make it possible for healthcare providers and clinical researchers to process an unprecedented amount of data from medical scans. Furthermore, Quibim’s AI-powered imaging solutions will empower pharmaceutical companies to enhance clinical trials and accelerate drug development using precise, actionable insights derived from imaging biomarkers.
For better understanding, since its inception, Quibim has focused on delivering a complete, non-invasive understanding of every tissue point in the human body, at any moment in time. The company’s pathway to achieve that includes conceiving foundational AI models applied to imaging that extract actionable insights from MRI, CT, and PET scans. The stated insights, on their part, facilitate precise characterization of phenotypes and prediction of outcomes in areas, such as oncology, immunology, neurology and metabolic disorders.
“Quibim’s technology exemplifies the next wave of precision medicine,” said José Mesa, Partner at Columbus and Buenavista’s representative on the Board. “Their impressive track record with global pharmaceutical partnerships, including partnerships with companies such as Merck KGaA and Philips, exemplify Quibim’s role in transforming imaging data into valuable predictions for clinical trials and treatment planning. We expect that as Quibim develops its pipeline of companion diagnostic tools, we will see tremendous momentum for its technology and products.”
Talk about Quibim portfolio on a slightly deeper level, it includes QP-Prostate®, which happens to be the company’s flagship product. QP-Prostate® is specifically designed to enhance prostate cancer detection by leveraging an industry-leading AI-powered lesion detection facility.
Next up, we have the company’s QP-Brain® solution. This is essentially one AI-based early-stage neurological disease quantification software for quantification of early brain atrophy and lesions.
Then, there is QP-Liver®, an automated AI tool geared towards MR diagnosis of diffuse liver diseases through accurate quantification of tissue fat and iron levels.
Rounding up highlights would be QP-Insights®, which is a specialized platform focused on helping you manage, store and analyze multi-omics data in clinical trials and real-world data studies.
The solution’s excellence in what it does can also be understood once you consider QP-Insights is currently being used by global biopharmaceutical companies, academic medical centers and research consortiums, including the European Cancer Imaging Initiative to support Europe’s Beating Cancer Plan. It further manages the largest imaging datasets in the world, accounting for more than 100 million medical images.
Among other things, we ought to mention how Quibim enjoys more than 170 installations across healthcare institutions, research centers, hospitals, and clinical facilities. This it was able to realize after achieving regulatory clearances across the US, EU, UK, and various other regions.
“Quibim’s mission is to turn imaging into a catalyst for precision health, and we are deeply grateful to both our new and current investors for their support,” said Dr. Ángel Alberich-Bayarri, CEO and co-founder of Quibim. “Our global expansion into the U.S. is a critical milestone as we work with pharmaceutical leaders and healthcare providers to unlock the power of imaging to revolutionize diagnostics and improve patient outcomes.”
